Javadpour N, Soares T
Cancer. 1981 Nov 15;48(10):2279-81. doi: 10.1002/1097-0142(19811115)48:10<2279::aid-cncr2820481025>3.0.co;2-e.
The rates of false-positive and false-negative serum alpha-feto protein (AFP) and human chorionic gonadotropin (HCG) determinations in 50 patients with testicular cancer utilizing assays from a reference laboratory were studied. Seven (14%) of fifty patients had false-positive and one (2%) of 50 had false-negative serum HCG determinations. Although six (12%) of 50 of serum AFP determinations showed false-positive results; no false-negative rates were encountered for serum AFP. Utilizing simultaneous measurements of serum HCG and luteinizing hormone (LH) measuring urinary HCG by a highly specific carboxyl-terminal assay, one may rule out false-positive occurrences of serum HCG in patients with testicular cancer. This double-blind study also confirmed the need for correlating the clinical status of the patients with elevated serum AFP or HCG in patients with testicular cancer before embarking on any therapy.
利用一家参考实验室的检测方法，对50例睾丸癌患者血清甲胎蛋白（AFP）和人绒毛膜促性腺激素（HCG）检测的假阳性和假阴性率进行了研究。50例患者中有7例（14%）血清HCG检测出现假阳性，50例中有1例（2%）出现假阴性。虽然50例中有6例（12%）血清AFP检测结果为假阳性，但未发现血清AFP的假阴性率。通过高特异性羧基末端检测法同时测量血清HCG和促黄体生成素（LH）以及检测尿HCG，可排除睾丸癌患者血清HCG的假阳性情况。这项双盲研究还证实，在对睾丸癌患者进行任何治疗之前，有必要将患者的临床状况与血清AFP或HCG升高情况相关联。
